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Abstract 
Nowadays scientists are looking for the new non-invasive markers to detect early stages of COPD 
exacerbation. The aim of our work was to compare the levels of NO in exhaled air of patients with stable 
COPD and in COPD patients with acute exacerbations. Also we evaluated the effect of continuous use of 
inhaled corticosteroids (ICS) on the exhaled NO level. The study included 61 patients with COPD (group 
1 – 38 patients in the stable phase, group 2 – 23 patients with exacerbation; group 3 – 11 healthy 
volunteers). Lung function, concentration of NO in exhaled air and assessment with mMRC scale were 
conducted in all patients. 
The analysis revealed that NO level in exhaled air during exacerbation of COPD was 24 [17-40] ppb, 
which is significantly higher in comparison with both patients with stable COPD (9,5 [7-12] ppb) and 
healthy people (12,0 [10,0-15,0] ppb ) (p <0,001). Therefore NO level in exhaled air determination can 
be used as one of the non-invasive markers of exacerbation in COPD for early start of enhanced therapy. 
Lung function, body mass index, height, weight and smoking history did not affect the concentration of 
NO in the exhaled air in patients with COPD either during exacerbation or remission. Also, we found no 
influence of prolonged therapy with ICS on NO levels in COPD patients, which can be due to the small 
size of the group. 
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1. Introduction  
Today, chronic obstructive pulmonary disease (COPD) remains one of the global health issues. 
According to the World Health Organization (WHO), more than three million people die of the 
disease exacerbation throughout the world each year 4. Exacerbation is a key problem of 
managing such patients as economic costs of treatment during flare-up periods become many 
times higher and frequent and persistent exacerbations considerably deteriorate quality of life 
of patients and cause early disability 4. 
Currently, researchers are actively looking for new non-invasive indicators to detect 
exacerbation of COPD at early stages. Exhaled nitric oxide (NO) levels is one of those modern 
markers. However, there are limited data reported in literature about the use of NO for COPD 
diagnose. 
Philip O'Reilly et al. (2007) in their studies have shown that NO levels in patients with acute 
COPD exacerbation are lower than those in patients with bronchial asthma (BA) but higher 
than in healthy volunteers. Accordingly, the authors have concluded that NO cannot be used as 
a reliable marker of early COPD exacerbations 7. At the same time, other authors have 
obtained results suggesting that in patients with severe COPD NO levels during their 
exacerbation periods were significantly higher than during remission 2. 
Several researchers have studied the seasonality effect on NO levels in COPD patients. It was 
found that NO levels were higher in a cold season, particularly, in autumn, possibly due to 
increased incidence of viral infections in that period of a year 2. 
According to other researchers, NO levels in smoking patients with stable COPD are much 
lower than those in non-smokers. However, there is no difference between former smokers and 
non-smokers 3, 5, 8. 
A number of researchers have demonstrated that unlike bronchodilators in those who suffer 
from bronchial asthma inhaled glucocorticosteroids (IGCSs) have no effect on NO levels in 
COPD patients [3]. At the same time, Z. Zietkowski et al. obtained an opposite result: 
according to their data, IGCS post-treatment NO levels were significantly lower in COPD 
patients [9]. 
Therefore, given quite contradictory evidence available to date the use of NO as a marker of 
COPD exacerbation as well as effects of IGCSs on NO levels still need investigating. 
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In this regard, we aimed to compare exhaled NO levels in 
COPD patients during remission and exacerbation periods and 
to assess the effect of continuous use of IGCSs on NO 
parameters. 
 
2. Materials and methods 
The study included 61 patients with verified COPD. COPD 
presence, severity and group as well as the pathological 
process phase were assessed in accordance with the criteria set 
out by the Ministry of Health of Ukraine in Order № 555 dated 
June 27, 2013 [6]. 
All subjects were assigned to 2 groups by disease stage. Group 
1 included 38 remitting patients, and Group 2 included 23 
subjects with exacerbation. All patients received a standard 
therapy according to their disease stages and groups. Control 
group 3 included 11 apparently healthy never-smoker 
volunteers with normal respiratory function (RF). 
During the study of the main groups, subjects were assigned to 
subgroups according to therapy they were receiving. Subgroup 
1a included remitting COPD patients on non-IGCS therapy, 
and subgroup 1b contained COPD patients who were receiving 
IGCSs. Subgroup 2a — exacerbation COPD patients not 
receiving IGCSs. Subgroup 2b — exacerbation COPD patients 
receiving IGCSs. 
COPD diagnosis in all patients was verified by using RF 
parameters measured with Master Lab system (Jaeger, 
Germany): levels of forced expiratory volume in one second 
(FEV1), forced vital capacity (FVC), FEV1/FVC ratio were 
analysed; reversibility of airflow obstruction was tested with a 
short-acting β2-agonist (salbutamol). Obstruction severity was 
assessed by using the post-bronchodilator test (according to 
Recommendations of the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD), 2013). 
Exhaled NO concentration was measured with Niox Mino 
system (Aerocrine, Sweden). 
All patients were asked to complete the mMRC dyspnea scale. 
Statistical analysis of the study data was performed with 
Statistika 6.1 software. Parametric statistics methods with 
calculation of mean values, standard deviation (M ± m) and 
the Student’s t test were used for normally distributed 
variables. Non-parametric statistics methods with calculation 
of Med median and quartiles [25%–75%], Mann-Whitney and 
Kruskal-Wallis tests of significance were used for not 
normally distributed parameters. Findings were considered to 
be statistically significant at p < 0.05. Significance of 
differences by quality and binary parameters was assessed by 
using the chi-square (χ2) test where n < 5 by using the Fishers 
exact test for frequencies. Correlation analysis of exhaled NO 
level and RF parameters was also performed by using the 
Spearman’s rank correlation coefficient (R). 
 
3. Results and discussion 
Groups of patients and subjects in the control group were 
comparable by age, sex, weight and BMI. Groups of COPD 
patients did not differ significantly by number of smokers, 
pack-year value or history of the disease. The number of 
exacerbations per year was significantly higher in patients who 
had flare-ups at the time of the study examination (Table 1). 
 
Table 1: Comparison Group Description 
 
Parameter Group, n P Group 1, n=38 Group 2, n=23 Group 3, n=11 
Gender, n (%) m=32; (84.2) f=6; (15.8) 
m=21; (91.3) 
f=2; (8.7) 
m=10; (90.9) 
f=1; (9.01) 
p1-2=0.43; 
p1-3=0.58; 
p2-3=0.97; 
Age, М±m, years 64.07±1.23 65.26±2.07 57.72 ± 2.87 
p1-2=0.51; 
p1-3=1.0; 
p2-3=1.0; 
Weight, 
Меd[25%-75%] 80 [72-86] 80 [60-89] 76[72-86] 
p1-2=0.56; 
p1-3=0.9; 
p2-3=0.65; 
Smoking, n (%) 17 (44,7) 8 (34,8) - p1-2=0.44; 
BMI, kg/m2 
Меd[25%-75%] 27.5 [23-30] 25 [23-29] 24 [22-28] 
p1-2=0.34; 
p1-3=0.23; 
p2-3=0.63; 
Pack-year value, Меd[25%-75%] 39 [22-60] 37 [15-45] - p1-2=0.67; 
Disease history, Меd[25%-75%] 5 [3-9] 3,5 [2-10] - p1-2=0.69; 
Number of exacerbations per year Меd[25%-75%] 1.0 [0-3,0] 2.0 [1.0-4.0] - p1-2=0.00; 
 
Assessment of lung function detected that FEV1 value was 
expectedly significantly lower than in patients from Group 1 
and Group 2 versus healthy volunteers. And in patients with 
exacerbation FEV1 was also significantly lower than in 
remitting patients. At the same time, though FVC was 
significantly lower in patients from Groups 1 and 2 versus 
Group 3, the difference by this parameter was not significant 
between patients with exacerbation and those with stable 
COPD (Table 2). 
 
Table 2: Study Group Description 
 
Parameter Group, n P Group 1, n=38 Group 2, n=23 Group 3, n=11 
FEV1, Меd[25%-75%] 51.5 [42.8-63.2] 40.1[32-52.6] 97.0 [90.0-100.0] 
p1-2=0.01; 
p1-3=0.00; 
p2-3=0.00; 
FVC, Меd[25%-75%] 87.2[81.8-91.4] 84.6[69.1-95.7] 102.0[98.0-110.0] 
p1-2=0.12; 
p1-3=0.00; 
p2-3=0.00; 
FEV1/FVC, Меd[25%-75%] 0.45[0.39-0.56] 0,38[0.32-0.57] 0,89[0.82-0.91] 
p1-2=0.23; 
p1-3=0.00; 
p2-3=0.00; 
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It also seemed appropriate to define the composition of the 
main comparison groups in accordance with the principles of 
the new COPD classification 1, 9. It is found that there were 
patients of all categories in the stable patient group. Group C 
included the most number of patients, i.e. patients with minor 
clinical symptoms but severe obstruction and/or a history of 
exacerbations. In contrast to Group 1, Group 2 did not include 
any category a patients while Group D was the dominant one 
containing significantly more such patients versus the 
remitting patient group (Table 3). 
 
Table 3: Study Subjects Distributed by COPD Groups 
 
Classification Group Group 1, n=38 Group 2, n=23 P 
A, n (%) 5 (13.2%) 0 0.18 
B, n (%) 9 (23.7%) 4 (17.4%) 0.56 
C, n (%) 17 (44.7%) 7 (30.4%) 0.27 
D, n (%) 7 (18.4%) 12 (52.2%) 0.00 
 
Analysis of exhaled of NO levels helped determine that in 
Group 2 this parameter was significantly higher than in Group 
1 (24 [17-40] ppb and 9.5 [7-12] ppb, respectively). In Group 
3, this value was 12.0 [10,0-15,0] ppb and significantly 
(p < 0.001) lower than in Group 2. As for the remission period, 
NO levels in all patients in Group 1 was within the normal 
range and did not differ significantly from that of the control 
group. It is noteworthy, however, that minimum and maximum 
variance of the parameters was greater in Group 1 versus 
Group 3 (Fig. 1). 
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Fig 1: NO Values in Comparison Groups 
 
Correlation analysis performed for COPD patients showed no 
correlation between exhaled NO levels and RF values in any 
of the comparison groups or in the general patient population 
(Table 4). 
 
Table 4: RF/NO Correlation 
 
Study Correlations Group 1 Group 2 R Р R Р 
FEV1 and NO 0,27 0.1 -0.27 0.22 
FVC and NO 0,17 0.29 -0.02 0.91 
FEV1/FVC and NO 0,09 0.58 -0.23 0.33 
 
We found no significant correlation between NO and height, 
weight and the pack/year value (Table 5). 
Table 5: Anthropometric Indicators/Pack-Year Value to NO Levels 
Correlation 
 
Study Correlations Group 1 Group 2 R P P R 
Height and NO -0.02 0.88 0.07 0.74 
Weight and NO -0.1 0.56 0.29 0.18 
Pack-year value and NO -0.27 0.1 0.22 0.32 
 
No significant correlation between exhaled NO levels and the 
number of exacerbations a year (R = 0.065, р = 0.7 and 
R = 0.046, р = 0.8) was found in patients from Group 1 or 
Group 2. 
Classification of patients by received treatment helped 
determine that NO did not differ significantly in patients 
treated or not treated with IGCSs for COPD exacerbation or 
during remission of the disease (Table 6). 
 
Table 6: NO Levels/IGCSs Dependence 
 
Parameter Subgroup 
1а 
Subgroup 
1b 
Subgroup 
2а 
Subgroup 
2b 
Number of 
Patients, n 
(%) 
20 
(31.7%) 
18 
(28.6%) 
10 
(15.9%) 
13 
(23.8%) 
NO, Меd 
[25%-75%] 
8,5 
[7.0-12.5] 
10,5 
[7.0-12.0] 
27,5 
[15.0-
40.0] 
12,0 
[17.0-
29.0] 
Notes:  
Р1а-1b– 0.81;  
Р1а-2а– 0.001;  
Р1а-2b– 0.00;  
Р1b-2а – 0.001;  
Р1b-2b – 0.001;  
Р2а-2b– 0.95. 
 
4. Conclusions 
1. In patients with exacerbation of COPD level of NO in 
exhaled air was 24 [17-40] ppb, which is significantly (p < 
0,001) higher compared with healthy people (12,0 [10,0-
15,0] ppb) and patients with disease in stable phase (9,5 
[7-12] ppb). 
2. Determining the level of NO in exhaled air can be used as 
one of the non-invasive markers of exacerbations in 
COPD for early start of more intensive therapy. 
3. Lung function (FEV1, FVC, FEV1/FVC), BMI, height, 
weight and smoking history did not affect the 
concentration of NO in exhaled air in COPD patients 
either during exacerbation, or during remission. 
4. Regular intake of inhaled corticosteroids had no influence 
on the level of exhaled NO in COPD patients, which may 
be due to the small size of the comparison group. 
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